z-logo
open-access-imgOpen Access
A surrogate marker for Aβ42 production in the CNS
Author(s) -
Holtzman David M.
Publication year - 2009
Publication title -
embo molecular medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 4.923
H-Index - 107
eISSN - 1757-4684
pISSN - 1757-4676
DOI - 10.1002/emmm.200900030
Subject(s) - surrogate endpoint , production (economics) , medicine , economics , macroeconomics
Alzheimer's disease (AD) is the most common cause of dementia. There are currently no effective treatments that may delay the onset, slow the progression or prevent the disease. Unless such treatments are developed, the number of AD cases is expected to double in the next 30 years. There is overwhelming genetic and biochemical evidence that the aggregation and buildup of the amyloid‐β (Aβ) peptide plays a critical role in AD pathogenesis.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here